

**Translation**

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation  
February 26, 2025

**Notice Regarding the Establishment of the Pharmaceutical Sales Strategy Committee  
in Alfresa Corporation**

Alfresa Holdings Corporation (hereinafter, “the Company”) has decided to establish the Pharmaceutical Sales Strategy Committee (“the Committee”) in its subsidiary Alfresa Corporation (“Alfresa”) on April 1, 2025, to strengthen the structure of the Group’s Ethical Pharmaceuticals Wholesaling Business. Details are as follows.

**1. Purpose of Establishment of the Committee**

As per the announcement dated December 24, 2024, the Company established the Preparatory Committee for the Transfer of the Group Medical Wholesaling Business Management Department on January 1, 2025, and has been considering transferring the functions of the Group Medical Wholesaling Business Management Department to its subsidiary Alfresa.

We now have decided to establish the Committee within Alfresa, to further strengthen group governance in the Ethical Pharmaceuticals Wholesaling Business, the core business of the Group, and to enhance the capabilities to make decisions on business challenges and swiftly carry out Groupwide initiatives.

The Committee will work to realize a Groupwide operational structure for the Ethical Pharmaceuticals Wholesaling Business, and to further strengthen collaboration across the Group, thereby building a structure for uniformly providing high-functionality, high-quality services nationwide. With this, we will accelerate the initiatives to achieve the goals of the Alfresa Group’s Medium- to Long-Term Vision,<sup>\*1</sup> which was formulated as the medium- to long-term business strategy as well as the financial and capital strategies for the period through to fiscal 2032. Through these efforts, we will further contribute to the health of local communities and the prosperity of our customers and business partners.

<sup>\*1</sup> Reference: Notice regarding the Formulation of the Alfresa Group’s Medium- to Long-Term

Vision (published on May 15, 2023, on the Alfresa Holdings Corporation corporate website)  
[https://www.alfresa.com/eng/ir/pdf/mediumtolog\\_termvision.pdf](https://www.alfresa.com/eng/ir/pdf/mediumtolog_termvision.pdf)

## 2. Composition of the Committee

Chair	Yusuke Fukujin, Representative Director & President, Alfresa Corporation, Representative Director & Executive Vice President, Ethical Pharmaceuticals Wholesaling Business, International Business, Alfresa Holdings Corporation
Vice Chairs	Yosuke Kiyoshita, Representative Director & President, Shikoku Alfresa Corporation
	Takuji Takahashi, Representative Director & President, TS Alfresa Corporation
	Hiromitsu Kawajiri, Representative Director & President, Meisho Co., Ltd.
	Katsuya Higa, Representative Director & President, RYUYAKU CO., LTD.
	Shinya Uchida, Representative Director & President, Tohoku Alfresa Corporation
	Makoto Sakakibara, Representative Director & President, Miyazaki Onsendo Shoten Co., Ltd
Assistant Chair	Yoshihisa Yamada, Director, Vice President & Executive Officer, General Manager of Medical Sales Division, Alfresa Corporation
Members	Hironori Miyake, Executive Officer, General Manager of Kitakanto & Ko-Shin-Etsu Regional Office, Medical Sales Division, Alfresa Corporation
	Kazuhito Matsui, Vice President & Executive Officer, General Manager of Tokyo Regional Office, Medical Sales Division, Alfresa Corporation
	Hideyoshi Osaku, Executive Officer, General Manager of Shutoken Regional Office, Medical Sales Division, Alfresa Corporation
	Kenji Makino, Executive Officer, General Manager of Tokai Regional Office, Medical Sales Division, Alfresa Corporation
	Masaki Yoshioka, Executive Officer, General Manager of Kansai Regional Office, Medical Sales Division, Alfresa Corporation
	Shigeo Izumi, Officer, General Manager of Kyushu Regional Office, Medical Sales Division, Alfresa Corporation
	Akira Akazawa, Executive Officer, General Manager of Marketing Office for Nationwide Customers and Sales Department-Dispensing Pharmacy, Medical Sales Division, Alfresa Corporation
	Daisuke Miyauchi, Executive Officer, General Manager of Sales Division, Shikoku Alfresa Corporation
	Kazuhiko Kakimura, Director and Senior Executive Officer, Chief Sales Officer, TS Alfresa Corporation
	Masato Tamamura, Director, Managing Executive Officer, General Manager of Medicine Sales Division, Manager of Medicine Sales Promotion, Meisho Co., Ltd.

	Futoshi Tatetsu, Director, Executive Officer, General Manager of Sales Division and Manager of Sales Operations Management Department, RYUYAKU CO., LTD.
	Takeshi Kuriki, Director and Manager Executive Officer, General Manager of Sales Division, Tohoku Alfresa Corporation
	Akiyoshi Kakihara, Director, General Manager of Sales Division, Miyazaki Onsendo Shoten Co., Ltd
Advisors	Ryuji Arakawa, Representative Director & Chairman, Alfresa Corporation, Representative Director & President, Alfresa Holdings Corporation
	Shigeki Ohashi, Director, Vice President & Executive Officer, Group Business Strategy, Alfresa Holdings Corporation,

(Note) Positions are as of April 1, 2025.

#### About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥2.8 trillion for the fiscal year ended March 31, 2024. For more information, please see: <https://www.alfresa.com/eng/>